These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32053815)

  • 1. Expression of Receptor Tyrosine Kinases on Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes in Patients with Renal Cell Carcinoma and Healthy Donors.
    Tsimafeyeu I; Volkova M; Olshanskaia A; Raskin G; Aschuba S; Khochenkova Y; Bondarenko A; Khochenkov D
    Oncology; 2020; 98(4):252-258. PubMed ID: 32053815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma.
    Hu B; Sun M; Wang Z; Zheng Y; Cai W; Shi HH; Zhuang Y; Lin Q
    Clin Chem; 2020 Sep; 66(9):1219-1227. PubMed ID: 32870999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune inhibitory effects of renal cell carcinoma extract on lectin and alloantigen-induced peripheral blood and tumor infiltrating lymphocyte blastogenesis.
    Shabtai M; Ye H; Kono K; Takayam T; Terashima K; Tsukuda K; Frischer Z; Waltzer WC; Malinowski K
    Urol Oncol; 2003; 21(1):27-32. PubMed ID: 12684124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.
    Baine MK; Turcu G; Zito CR; Adeniran AJ; Camp RL; Chen L; Kluger HM; Jilaveanu LB
    Oncotarget; 2015 Sep; 6(28):24990-5002. PubMed ID: 26317902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
    Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
    BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma.
    Kowalczyk D; Skorupski W; Kwias Z; Nowak J
    Br J Urol; 1997 Oct; 80(4):543-7. PubMed ID: 9352689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
    Thompson RH; Dong H; Lohse CM; Leibovich BC; Blute ML; Cheville JC; Kwon ED
    Clin Cancer Res; 2007 Mar; 13(6):1757-61. PubMed ID: 17363529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.
    Alaghehbandan R; Stehlik J; Trpkov K; Magi-Galluzzi C; Condom Mundo E; Pane Foix M; Berney D; Sibony M; Suster S; Agaimy A; Montiel DP; Pivovarcikova K; Michalova K; Daum O; Ondic O; Rotterova P; Dusek M; Hora M; Michal M; Hes O
    Ann Diagn Pathol; 2017 Aug; 29():17-22. PubMed ID: 28807336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.
    MacFarlane AW; Jillab M; Plimack ER; Hudes GR; Uzzo RG; Litwin S; Dulaimi E; Al-Saleem T; Campbell KS
    Cancer Immunol Res; 2014 Apr; 2(4):320-31. PubMed ID: 24764579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
    Abbas M; Steffens S; Bellut M; Becker JU; Großhennig A; Eggers H; Wegener G; Kuczyk MA; Kreipe HH; Grünwald V; Schrader AJ; Ivanyi P
    Med Oncol; 2016 Jun; 33(6):59. PubMed ID: 27165272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
    Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
    Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
    Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
    Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
    Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
    Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
    Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes.
    Riccobon A; Gunelli R; Ridolfi R; De Paola F; Flamini E; Fiori M; Saltutti C; Petrini M; Fiammenghi L; Stefanelli M; Granato AM; Cuzzocrea DE; Amadori D
    Cancer Invest; 2004; 22(6):871-7. PubMed ID: 15641485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.